A blood test developed at Washington University School of Medicine in St. Louis has proven highly accurate in detecting early signs of Alzheimer’s disease in a study involving nearly 500 patients from across three continents, providing further evidence that the test should be considered for routine screening and diagnosis.
The international study shows that when the blood test is combined with genetic risk factors, the test is up to 93% accurate at identifying people at risk of Alzheimer's disease.
Known as Precivity AD, the commercial version of the test is marketed by C2N Diagnostics, a Washington University startup founded by the researchers.




Subscribe now ➤ https://bit.ly/2NNQiyM

For more great content from the Higher Education Channel check us out at:
Facebook ➤ http://bit.ly/1WPZEek
Twitter ➤ http://bit.ly/22qZDNU
Instagram ➤ http://bit.ly/1THSOnM